August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS41
Academic Journal
Presents an abstract of the research manuscript `Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats,' by E.L. Schiffrin and A. Turgeon from the University of Montreal.


Related Articles

  • Hypertension.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS36 

    Presents an abstract of the research manuscript `Effect of chronic treatment with two different ETA-selective endothelin receptor antagonists on blood pressure and small artery structure of DOCA-salt hypertensive rats,' by E.L. Schiffrin, J.-S. Li and A. Turgeon from the University of Montreal.

  • Hypertension.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS36 

    Presents an abstract of the research manuscript `The ETA/B receptor antagonist bosentan reduces blood pressure in rats with reduced renal mass,' by R. Lariviere, S. Lacasse-M. et al from the Laval University. Endothelin-1 (ET).

  • Nonselective ETA/ETB-receptor blockade increases systemic blood pressure of Bio 14.6 cardiomyopathic hamsters. Honoré, Jean-Claude; Carrier, Émilie; Fecteau, Marie-Hélène; Tirapelli, Carlos R.; Bkaily, Ghassan; D'Orleans-Juste, Pedro // Canadian Journal of Physiology & Pharmacology;Jun2008, Vol. 86 Issue 6, p394 

    To examine the role of endothelin ETA and ETB receptors in congestive heart failure due to cardiomyopathy, the effect of chronic treatment with selective ETA- and ETB-receptor antagonists (atrasentan and A-192621, respectively), alone and in combination, was assessed on functional and...

  • Endothelin May Contribute to Elevated BP.  // Kidney;Nov/Dec98, Vol. 7 Issue 6, p274 

    Presents an abstract of the study 'Endothelin May Contribute to Elevated BP,' by H. Krum et al published in 1998.

  • Primary hypertension at a single center: treatment, time to control, and extended follow-up. DiPietro, Amy; Kees-Folts, Deborah; DesHarnais, Susan; Camacho, Fabian; Wassner, Steven Joel // Pediatric Nephrology;Dec2009, Vol. 24 Issue 12, p2421 

    We present data on presentation, treatment, and follow-up of 65 pediatric patients with primary hypertension treated over the past 12 years, including initial anthropometric data, pharmacologic treatment, time to control for both systolic and diastolic blood pressure (SBP/DBP), and maintenance...

  • DORADO: Darusentan lowered BP in patients with resistant hypertension. Raible, Eric // Cardiology Today;Jun2009, Vol. 12 Issue 6, p15 

    The article discusses research which found the effectiveness of Darusentan, an oral endothelin antagonist, in lowering blood pressure in patients with resistant hypertension.

  • Bosentan Therapy for Pulmonary Arterial Hypertension. Rubin, Lewis J.; Badesch, David B.; Barst, Robyn J.; Galiè, Nazzareno; Black, Carol M.; Keogh, Anne; Pulido, Tomas; Frost, Adaani; Roux, Sébastien; Leconte, Isabelle; Landzberg, Michael; Simonneau, Gérald // New England Journal of Medicine;3/21/2002, Vol. 346 Issue 12, p896 

    Background: Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present...

  • DOCA-salt treatment enhances responses to endothelin-1 in murine corpus cavernosum. Carneiro, Fernando S.; Giachini, Fernanda R.C.; Lima, Victor V.; Carneiro, Zidonia N.; Nunes, Kênia P.; Ergul, Adviye; Leite, Romulo; Tostes, Rita C.; Webb, R. Clinton // Canadian Journal of Physiology & Pharmacology;Jun2008, Vol. 86 Issue 6, p320 

    The penis is kept in the flaccid state mainly via a tonic activity of norepinephrine and endothelins (ETs). ET-1 is important in salt-sensitive forms of hypertension. We hypothesized that cavernosal responses to ET-1 are enhanced in deoxycorticosterone acetate (DOCA)-salt mice and that blockade...

  • Endothelin Receptor Antagonists - An Overview. Dasgupta, Falguni; Mukherjee, Ashis K.; Gangadhar, N. // Current Medicinal Chemistry;Mar2002, Vol. 9 Issue 5, p549 

    In thirteen years since the appearance of Endothelin (ET) on the international scene, possibility of its involvement in a variety of diseases has attracted the attention of medicinal chemists in search of novel therapeutics for various cardiovascular diseases (CVDs). Discovery of pharmaceutical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics